Future Developments of Clinical Research in Pediatrics: The Role of the Journal Klinische Pädiatrie

Recently, in German a new law – “Patientenrechtegesetz” §630aBGBff – was signed by the government to strengthen patients’ rights providing best care. A prerequisite for best care are conclusive information on diagnostics, treatment and prognosis. Thus, the relevance of clinical trials and clinical registries providing sufficient data for evidence-based medicine will increase during the next years. Therefore appropriate generating of the studies hypothesis, sample size calculations and study management apart from project funding as well as rapid information of the respective scientific community are of crucial importance. The lack of clinical evidence from Cochrane analyses in neonatology and other fields from pediatrics underlines this statement [12] [13.]

• References

• 1 Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med 2005; 10: 115-122
• 2 Crandall W, Kappelman MD, Colletti RB et al. ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis 2011; 17: 450-457
• 3 Fulda S. Molecular Targeted therapies for rhabdomyosarcoma: Focus on hedgehog and apoptosis signaling. Klin Padiatr 2013; Apr 26. [Epub ahead of print]
• 4 Gathmann B, Grimbacher B, Kindle G et al. The German National Registry for Primary Immunodeficiencies (PID). Clin Exp Immunol 2013; Mar 15. [Epub ahead of print]
• 5 Göbel U, Gortner L. The impact factor is volatile and sensitive. Klin Padiatr 2012; 224: 285-290
• 6 Göbel U, Heinrich B, Krauth KA et al. Process and outcome quality of the German Paediatric Surveillance Unit. Klin Padiatr 2010; 222: 92-97
• 7 Göpel W, Kribs A, Ziegler A et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011; 378: 1627-1634
• 8 Grunewald TG, Greulich N, Kontny U et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 2012; 224: 124-131
• 9 Harari S, Cottin V, Humbert M. Gobal effort against rare and orphan disease. Eur Respir Rev 2012; 21: 171-172
• 10 Krudewig J, Baumann U, Bernuth von H et al. Arbeitsgemeinschaft Pädiatrische Immunologie e. V. (API). Interdisciplinary AWMF guideline for the treatment of primary antibody deficiencies. Klin Padiatr 2012; 224: 404-415
• 11 Masoodi I, Alsayari K, Albishri J. Inflammatory bowel disease register: Steps towards Crohn’s & colitis foundation of Saudi Arabia (CCFSA). Int J Health Sci (Qassim) 2012; 6: 232-236
• 12 Meyer S, Willhelm C, Girisch W et al. The role of developing countries in generating Cochrane meta-analyses in the field of pediatrics (neo­natology and neuropediatrics): a systematic analysis. World Health Popul 2013; 14: 24-32
• 13 Meyer S, Schroeder N, Willhelm C et al. Clinical recommendations of Cochrane reviews in 3 different fields of paediatrics (Neonatology, neuropaediatrics, and complementary and alternative medicine): A systematic analysis. Pediatr Int 2013; Apr 8 [Epub ahead of print]
• 14 Minden K, Klotsche J, Niewerth M et al. Biologics register JuMBO: Long-term safety of biologic therapy of juvenile idiopathic arthritis. Z Rheumatol 2013; 72: 339-346
• 15 Nguyen KA, Claris O, Kassai B. Unlicensed and off-label drug use in a neonatal unit in France. Acta Paediatr 2011; 100: 615-617
• 16 Neubert J, Niehues T, Baumann U et al. Leitlinie der Pädiatrische Arbeitsgemeinschaft AIDS (PAAD) e.V. zur antiretroviralen Therapie bei HIV-infizierten Kindern und Jugendlichen. Klin Padiatr 2012; 224: 98-110
• 17 Schultze-Florey RE, Graf N, Vorwerk P et al. DICER1 Syndrome: A new cancer syndrome. Klin Padiatr 2013; Apr 26. [Epub ahead of print]
• 18 Stichtenoth G, Demmert M, Bohnhorst B et al. Major contributors to hospital mortality in very-low-birth-weight infants: data of the birth year 2010 cohort of the German Neonatal Network. Klin Padiatr 2012; 224: 276-281
• 19 Witt O, Milde T, Deubzer HE et al. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr 2012; 224: 398-403